Analyst Price Targets — MEDP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 6, 2026 11:13 am | Luke Sergott | Barclays | $500.00 | $468.36 | StreetInsider | Barclays Upgrades Medpace (MEDP) to Equalweight |
| February 13, 2026 10:19 am | David Windley | Jefferies | $560.00 | $416.04 | TheFly | Medpace upgraded to Buy from Hold at Jefferies |
| February 11, 2026 1:44 pm | — | Truist Financial | $539.00 | $431.17 | TheFly | Medpace price target lowered to $539 from $555 at Truist |
| February 11, 2026 12:55 pm | — | Mizuho Securities | $582.00 | $446.05 | TheFly | Medpace price target lowered to $582 from $660 at Mizuho |
| February 11, 2026 12:07 pm | — | BMO Capital | $460.00 | $446.05 | TheFly | Medpace price target lowered to $460 from $600 at BMO Capital |
| February 10, 2026 6:49 pm | — | Robert W. Baird | $564.00 | $455.64 | TheFly | Medpace upgraded to Outperform from Neutral at Baird |
| January 9, 2026 12:09 pm | — | Mizuho Securities | $660.00 | $600.02 | TheFly | Medpace price target raised to $660 from $655 at Mizuho |
| December 15, 2025 10:55 am | Luke Sergott | Barclays | $525.00 | $557.78 | TheFly | Medpace price target raised to $525 from $485 at Barclays |
| October 27, 2025 1:50 pm | Jailendra Singh | Truist Financial | $555.00 | $605.20 | TheFly | Medpace price target raised to $555 from $436 at Truist |
| October 24, 2025 12:08 pm | — | Robert W. Baird | $613.00 | $596.61 | TheFly | Medpace price target raised to $613 from $491 at Baird |
Latest News for MEDP
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Medpace (MEDP) To Contact Him Directly To Discuss Their Options
New York, New York--(Newsfile Corp. - April 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.
LOS ANGELES, April 16, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP) have opportunity to lead the securities fraud class action lawsuit.
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Medpace between April 22, 2025 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MEDP.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.